Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
A young mom battling stage 4 cancer says she was supposed to start a clinical trial at the National Institutes of Health in just a few weeks — but she was left in limbo after her doctors told ...
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
But with the government talking of an AI revolution, one trial has used the tech to drastically reduce the volume of minutes spent on hold. Citizens Advice teams in Stockport, Oldham, Rochdale and ...
Researchers from the University of Seville and the University of Cadiz, coordinated by the professors of Physiology Pedro ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted ... lifted in 2022 after an investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results